KR100947353B1 - Healthy food composition for improving sleep disturbance and a good-sleep - Google Patents
Healthy food composition for improving sleep disturbance and a good-sleep Download PDFInfo
- Publication number
- KR100947353B1 KR100947353B1 KR1020090086019A KR20090086019A KR100947353B1 KR 100947353 B1 KR100947353 B1 KR 100947353B1 KR 1020090086019 A KR1020090086019 A KR 1020090086019A KR 20090086019 A KR20090086019 A KR 20090086019A KR 100947353 B1 KR100947353 B1 KR 100947353B1
- Authority
- KR
- South Korea
- Prior art keywords
- sleep
- dried
- food composition
- improving
- goodnight
- Prior art date
Links
- 208000019116 sleep disease Diseases 0.000 title claims abstract description 21
- 239000000203 mixture Substances 0.000 title claims abstract description 18
- 235000001497 healthy food Nutrition 0.000 title description 3
- 208000022925 sleep disturbance Diseases 0.000 title 1
- 240000002853 Nelumbo nucifera Species 0.000 claims abstract description 19
- 235000006508 Nelumbo nucifera Nutrition 0.000 claims abstract description 19
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 claims abstract description 12
- 244000205754 Colocasia esculenta Species 0.000 claims abstract description 11
- 235000006481 Colocasia esculenta Nutrition 0.000 claims abstract description 11
- 235000013402 health food Nutrition 0.000 claims abstract description 8
- 229910001629 magnesium chloride Inorganic materials 0.000 claims abstract description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 5
- 235000013372 meat Nutrition 0.000 claims description 4
- 240000005979 Hordeum vulgare Species 0.000 claims 1
- 235000007340 Hordeum vulgare Nutrition 0.000 claims 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 abstract description 12
- 206010022437 insomnia Diseases 0.000 abstract description 12
- 239000006187 pill Substances 0.000 abstract description 7
- 239000000843 powder Substances 0.000 abstract description 6
- 208000020685 sleep-wake disease Diseases 0.000 abstract description 5
- 238000004519 manufacturing process Methods 0.000 abstract description 4
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 abstract description 3
- 238000001035 drying Methods 0.000 abstract description 3
- 239000011777 magnesium Substances 0.000 abstract description 3
- 229910052749 magnesium Inorganic materials 0.000 abstract description 3
- 230000001939 inductive effect Effects 0.000 abstract description 2
- 210000000582 semen Anatomy 0.000 abstract 2
- 239000009444 Nelumbinis Semen Substances 0.000 abstract 1
- 229960003987 melatonin Drugs 0.000 description 23
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 description 22
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 description 22
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 21
- DIWRORZWFLOCLC-HNNXBMFYSA-N (3s)-7-chloro-5-(2-chlorophenyl)-3-hydroxy-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound N([C@H](C(NC1=CC=C(Cl)C=C11)=O)O)=C1C1=CC=CC=C1Cl DIWRORZWFLOCLC-HNNXBMFYSA-N 0.000 description 16
- 229960004391 lorazepam Drugs 0.000 description 16
- 230000000694 effects Effects 0.000 description 15
- 238000012360 testing method Methods 0.000 description 15
- 238000002474 experimental method Methods 0.000 description 14
- 241000699670 Mus sp. Species 0.000 description 13
- 241000700159 Rattus Species 0.000 description 10
- 239000003814 drug Substances 0.000 description 10
- 238000000034 method Methods 0.000 description 10
- 239000000401 methanolic extract Substances 0.000 description 9
- 239000002994 raw material Substances 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- 235000013305 food Nutrition 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 230000011514 reflex Effects 0.000 description 6
- 230000004622 sleep time Effects 0.000 description 6
- 230000003860 sleep quality Effects 0.000 description 5
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 230000003340 mental effect Effects 0.000 description 4
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 4
- 229920000053 polysorbate 80 Polymers 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 208000019622 heart disease Diseases 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 230000035882 stress Effects 0.000 description 3
- 238000010998 test method Methods 0.000 description 3
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 239000000469 ethanolic extract Substances 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 206010016256 fatigue Diseases 0.000 description 2
- 235000013376 functional food Nutrition 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 235000001055 magnesium Nutrition 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 230000007659 motor function Effects 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000028527 righting reflex Effects 0.000 description 2
- 239000012488 sample solution Substances 0.000 description 2
- 230000036578 sleeping time Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- KYYSGHAGRQPUSK-UHFFFAOYSA-N 7-chloro-5-(2-chlorophenyl)-3-hydroxy-1,3-dihydro-1,4-benzodiazepin-2-one;ethanol Chemical compound CCO.C12=CC(Cl)=CC=C2NC(=O)C(O)N=C1C1=CC=CC=C1Cl KYYSGHAGRQPUSK-UHFFFAOYSA-N 0.000 description 1
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 206010003497 Asphyxia Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 102000018997 Growth Hormone Human genes 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 208000019914 Mental Fatigue Diseases 0.000 description 1
- 206010029216 Nervousness Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 208000010340 Sleep Deprivation Diseases 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 241001247821 Ziziphus Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229930002875 chlorophyll Natural products 0.000 description 1
- 235000019804 chlorophyll Nutrition 0.000 description 1
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 1
- 229940124579 cold medicine Drugs 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 206010013663 drug dependence Diseases 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 208000018685 gastrointestinal system disease Diseases 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 210000002161 motor neuron Anatomy 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 229940124595 oriental medicine Drugs 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 210000004560 pineal gland Anatomy 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000001020 rhythmical effect Effects 0.000 description 1
- 238000010825 rotarod performance test Methods 0.000 description 1
- 238000009987 spinning Methods 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 229940125725 tranquilizer Drugs 0.000 description 1
- 239000003204 tranquilizing agent Substances 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 210000001364 upper extremity Anatomy 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 230000002618 waking effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P10/00—Shaping or working of foodstuffs characterised by the products
- A23P10/20—Agglomerating; Granulating; Tabletting
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/322—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the nervous system or on mental function
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/21—Plant extracts
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Botany (AREA)
- Mycology (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
본 발명은 수면장애 개선과 쾌면을 위한 건강식품 조성물에 관한 것으로, 특히 천연물 중에서 쾌면에 도움을 준다고 알려진 산조인, 토란대, 연자육, 연근과 마그네슘으로 구성된 환으로 멜라토닌 함량이 높아 우수한 수면장애 개선 효능을 나타내는 수면 장애 개선과 쾌면을 위한 건강식품 조성물(이하에서 본 발명자가 임의로 명명한 "굿나잇"으로 함)에 관한 것이다.The present invention relates to a health food composition for improving sleep disorders and sleeping comfort, and particularly high in the content of melatonin in the ring composed of Sanjoin, tarodae, lotus root, lotus root and magnesium known to help comfort sleep among natural products showing an excellent sleep disorder improvement effect It relates to a health food composition (hereinafter referred to as "good night" arbitrarily named by the present inventors) for improving sleep disorders and sleeping comfort.
수면이란 눈이 감긴 채 의식 활동이 쉬는 상태를 말하며 우리가 낮 동안에 활동하느라 사용한 에너지를 보충하고 신체활동으로 인해 쌓인 피로를 회복하는 중요한 과정이다. 수면은 에너지와 피로 회복을 하는 시간일 뿐 아니라 사람의 성장에 꼭 필요한 성장호르몬이 가장 많이 분비되는 시간이다.Sleep is a state in which the conscious activity is closed with eyes closed and is an important process of replenishing the energy we used during the day and restoring the fatigue caused by physical activity. Sleep is not only a time to recover energy and fatigue, but also a time when the growth hormone is essential for human growth.
우리 몸에서 뇌는 생명 유지를 위한 모든 생리적 기능을 총괄하는 곳으로 이 뇌가 적절한 활동의 균형을 유지하기 위해서는 휴식이 필요하며 이러한 휴식은 대 부분 수면 시간에 이루어진다.In our body, the brain is responsible for all the physiological functions that maintain life, which requires rest for the brain to balance proper activity.
현대 생활의 소모적이고 바쁜 일상 속도, 비만 유병률의 증가, 인구의 고령화 등으로 수면 문제로 진단 받고 치료받는 환자의 숫자는 최근 수년간 증가해왔으며 향후에도 지속적으로 증가할 것으로 예상된다. 2005년 국립수면재단 조사에 의하면 활동하는 성인 10명중 거의 3명에서 과거 3개월간 수면 관련 문제로 결근하거나 작업에서 실수하였다고 밝혔다.The number of patients diagnosed and treated for sleep problems has increased in recent years and is expected to increase in the future, due to the exhausting and busy daily pace of modern life, increased prevalence of obesity, and aging population. According to the 2005 National Sleep Foundation survey, nearly three out of 10 adults have been absent from sleep-related problems or made mistakes in their work for the past three months.
수면 부족은 직접적으로 건강을 해치는데, 새로운 연구에 의하면 당뇨병, 심장질환, 비만에 걸릴 위험이 증가한다고 한다. 2004년에 발간된 저널 'Sleep'의 연구에서는 평균적으로 밤에 5시간 이하로 수면을 취한 여성은 7시간 수면을 취한 여성에 비해 사망률이 유의하게 높았다.Sleep deprivation directly harms your health, and new research shows an increased risk of diabetes, heart disease and obesity. In a 2004 study published in Sleep, women who slept less than five hours a night on average had significantly higher mortality rates than women who slept seven hours.
불면에 대해서는 수면제, 정신안정제, 스트레스 완화제 등의 투여가 일반적인 치료법으로서 사용되고 있다. 그러나 불면증 개선효과는 대상자의 심신적인 상태나 주위의 환경에 크게 좌우되는 동시에 사용한 약제의 작용점의 특징 외에 부작용이나 약물의존성 등의 이유로 제한되는 경우도 많다. For insomnia, the administration of sleeping pills, mental stabilizers, stress relief agents and the like are used as a general treatment. However, the effect of improving insomnia is largely dependent on the mental and physical condition of the subject and the surrounding environment, and at the same time, it is limited in terms of side effects and drug dependence, in addition to the characteristics of the action point of the used drug.
이런 이유로 외국에서는 수면주기를 조절하는 멜라토닌을 건강기능식품으로 복용하고 있다. 멜라토닌은 우리 뇌의 송과체에서 분비되는 호르몬으로 특히 일주기 리듬상 밤에 해당하는 시기에 집중적으로 분비된다. 멜라토닌은 대개의 경우 합성되어 만들지만, 드물지 않게 동물의 뇌에서 추출하기도 한다. 하지만 동물의 뇌 조직에서 얻는 물질을 복용하면 광우병에 걸릴 위험도 따르게 된다. For this reason, foreign countries are taking melatonin as a dietary supplement that regulates the sleep cycle. Melatonin is a hormone secreted by the pineal gland in our brain, especially during rhythmic nights. Melatonin is usually synthesized, but is rarely extracted from animal brains. However, taking substances from animal brain tissue also carries a risk of mad cow disease.
따라서 이들 수면제, 정신안정제, 스트레스 완화제, 시판되는 멜라토닌의 결 점을 개선하기 위해 새로운 의약품 및 기능성식품등의 개발이 필요로 된다.Therefore, it is necessary to develop new medicines and functional foods to improve the defects of these sleeping pills, mental stabilizers, stress relief agents, and melatonin on the market.
이에 본 발명에서는 상기한 바와 같은 여러 가지 부작용을 가진 수면제, 정신안정제, 스트레스 완화제, 시판 멜라토닌의 결점을 보완해주는 수면장애 개선 및 쾌면을 위한 굿나잇을 제공하는 것이다.Therefore, the present invention is to provide a good night for sleeping disorder improvement and sleeping comfort to compensate for the shortcomings of sleeping pills, mental stabilizers, stress relievers, commercial melatonin having various side effects as described above.
또 하나의 목적은 굿나잇의 멜라토닌의 수치 테스트, 굿나잇이 운동신경신경에 미치는 영향 및 수면연장시간의 동물실험을 통한 부작용 없는 수면장애 개선의 기능성 식품의 증명에 있다.Another purpose is to demonstrate functional foods for improving sleep disorders without side effects through good night melatonin level test, the effects of good night on motor neuron and animal experiments of extended time.
상기 과제를 해결하는 수단으로 생용(生用)하면 혈허에 의한 불면에 도움을 주는 것으로 한의원에서 주로 사용한다고 알려진 산조인과 불면증에 도움을 준다고 알려진 연자육, 연근, 토란대, 마그네슘을 정량에 맞게 배합하여 믹스, 제환, 건조 과정을 거쳐 쾌면에 도움을 주는 굿나잇을 개발하였다. If you use it as a means to solve the above problems, it helps to insomnia caused by blood loss, and mixes it with quantitative combinations of Yin-Jin, Lotus Root, Taro, and Magnesium which are known to help insomnia and Sanjoin, which is known to be mainly used in oriental medicine. After developing, reclaiming and drying, Good Night has been developed to help pleasant noodle.
동물에서 추출하거나 합성에 의한 멜라토닌이 인체 내에서 일으킬 수 있는 위험성을 최소화하기 위해 식품 중에도 보편적으로 사용하는 원료에서 멜라토닌이 다량 함유되어 있다고 알려진 원료만을 선정하여 제환하여 멜라토닌 원료에 대한 광우병 우려를 제거하였으며 천연 원료를 사용함으로써 인체의 중추신경계의 운동 기능에 대한 안정성을 확보하였다.In order to minimize the risk that melatonin can be extracted from animals or synthesized in the human body, only raw materials known to contain large amounts of melatonin are reclaimed from foods commonly used in foods to eliminate the risk of mad cow disease. The use of natural raw materials ensures the stability of the motor function of the human central nervous system.
본 발명의 수면장애 개선과 쾌면을 위한 건강식품에 대하여 높은 수치의 멜라토닌을 증명하였으며 불면증과 같은 수면장애를 완화 및 개선시켜 쾌면을 유도하고 수면제에 비해 운동신경과 같은 인체 안정성을 높이는 것을 확인함으로써 본 발명을 완성하였다.The present invention has demonstrated high levels of melatonin for healthy foods for improving sleep disorders and sleeping comfort of the present invention, and inducing sleep comfort by relieving and improving sleep disorders such as insomnia, and confirming that the human body such as exercise nerves are improved compared to sleeping pills. The invention was completed.
1. 수면장애 개선과 쾌면을 위한 건강식품 조성물(굿나잇)1.Healthy food composition for improving sleep disorder and sleeping comfort (Goodnight)
- 중량비로 미분쇄된 볶은 산조인 28.5%, 말린 연자육 24%, 말린 연근 24%, 말린 토란대 22%와, 염화마그네슘 1.5%를 정량한 혼합물을 물과 1:1비율로 배합하여 제환 후 75℃로 16시간 건조시킨 것이다.-Mix the mixture of 28.5% uncooked roasted acidjoin, dried lotus root meat 24%, dried lotus root 24%, dried taro bar 22%, and magnesium chloride 1.5% in 1: 1 ratio with water. It was dried for 16 hours.
산조인은 멧대추 씨앗의 껍데기로 <본초구전>에서 [생용하면 허열, 다면, 정신적 피로를 치료한다. 초숙하여 사용하면 진액을 수령하고 헐허에 의한 불면, 번갈, 허한을 치료한다.]라고 알려진 한방에서는 불면증 치료 및 우울증 치료로 상용화되어 사용하고 있는 약재이다. 이 약재는 볶아서 분말화하여 사용한다. 서울대 약대 박정일 교수는 볶은 산조인 성분이 본래 생 성분보다 잠을 더 자게 함으로써 흰쥐의 진정작용을 강하게 한다는 사실을 밝혔다.Sanjoin is the shell of the seed of the jujube, and in [Original Oral Medicine] he treats fever, multifaceted, and mental fatigue. If it is used prematurely, it receives the essence and treats insomnia, swelling, and suffocation caused by hull.] In Korean medicine, it is commonly used as a treatment for insomnia and depression. This medicine is roasted and powdered. Park Chung-il, a professor at Seoul National University, said that the roasted Sanjoin ingredients help to calm the rats by making them sleep more than the raw ingredients.
연자육과 연근은 연꽃의 성숙한 종자와 연꽃의 뿌리를 말하며 마음을 안정시 켜 불면증에 도움을 주는 식품으로 알려져 있으며 이를 건조하여 분말화하여 사용하였다. Lotus root and lotus root are the mature seeds of lotus and the root of lotus and are known as foods that help insomnia by calming the heart.
토란대는 천연 멜라토닌이 많이 함유되어 있는 식품으로 불면증에 도움을 주는 식품으로 알려져 있으며 가열시 독성이 파괴되므로 80℃에서 6시간 가열하여 분쇄하여 분말화 한다.Taro stand is a food that contains a lot of natural melatonin and is known as a food that helps insomnia. Toxic is destroyed when heated, so it is pulverized by heating at 80 ℃ for 6 hours.
염화마그네슘은 식물 색소인 엽록소의 구성 원소로써 부족시 정신장애, 불안, 신경과민, 우울증, 불면증을 발생시킬 수 있는 미네랄 성분이다.Magnesium chloride is a constituent of chlorophyll, a plant pigment, and it is a mineral that can cause mental disorders, anxiety, nervousness, depression, and insomnia when lacking.
2. 수면장애 개선과 쾌면을 위한 건강식품 조성물(굿나잇)의 제조방법2. Manufacturing method of health food composition (good night) for improving sleep disorder and sleeping comfort
이와 관련한 상세한 제조방법은 도1 의거하여 설명한다.Detailed manufacturing method in this regard will be described with reference to FIG.
본 발명에서 제공하는 수면장애 개선과 쾌면을 위한 건강식품 조성물의 제조방법은 1)원료 세척 및 가공, 2)이물선별(탈철, 탈분), 3)정량 및 믹스, 4)제환, 5)건조, 6)포장의 순서로 이루어진다.The present invention provides a method for preparing a health food composition for improving sleep disorders and sleeping comfort. 6) The packing takes place.
1) 원료 세척 및 가공1) raw material washing and processing
산조인과 연자육 및 연근과 토란대를 깨끗하게 세척한 후 산조인은 볶고, 연자육, 연근, 토란대는 말린다.Sanjoin and lotus root and lotus root and taro stand are washed clean, and Sanjoin is roasted, and lotus root, lotus root and taro stand are dried.
상기한 볶은 산조임 및 건조된 연자육 및 토란대를 분쇄기를 이용하여 각각 미분쇄한다.The roasted acid and dried soft meat and taro stand are pulverized using a grinder.
이때 분쇄된 입자는 60~70메시가 적당하다At this time, 60 ~ 70 mesh is suitable for crushed particles.
2)이물선별(탈철, 탈분)2) Foreign body sorting (de-iron, de-mineralization)
상기와 같이 원료를 분쇄과정에서 분쇄기 등으로부터 유입될 수 있는 쇳가루 등을 마그네트를 이용해서 탈철한다.As described above, iron powder, which can be introduced from a grinder or the like during the grinding process, is degassed using a magnet.
3)정량 및 믹스3) Quantitative and Mix
미분쇄한 각각의 원료를 정량하고, 이들을 교반기에 투입하여 믹스한다.The finely divided raw materials are quantified, and these are put into a stirrer and mixed.
상기 원료로는 중량비로 미분쇄된 볶은 산조인 28.5%, 말린 연자육 24% 및 말린 연근 24%, 말린 토란대 22%, 염화마그네슘 1.5%를 정량하여 교반기에 투입하며, 혼합원료의 중량과 동일한 중량으로 물을 투입하여 고루 섞이게 혼합 반죽한다.As the raw material, 28.5% of finely ground roasted sanjo, 24% of dried lotus root meat and 24% of dried lotus root, 24% of dried taro, 22% of magnesium chloride were added to the stirrer, and the water was the same as the weight of the mixed raw material. Pour the mixture to mix evenly.
4)제환4) Refund
상기와 같이 정량 믹스된 혼합원료를 제환한다. The mixed raw materials quantitatively mixed as described above are returned.
환의 크기는 지름 2~4mm가 적당하다.A suitable size of the ring is 2 to 4 mm in diameter.
5)건조5) Drying
제환된 본 발명 굿나잇을 75℃의 건조기를 이용하여 16시간 건조한다. 이때 함수율은 5%이하 정도가 적당하다.The refunded goodnight of the present invention is dried for 16 hours using a dryer at 75 ℃. At this time, the moisture content is about 5% or less.
이는 유통과정에서 변질의 우려가 없도록 함이다.This ensures that there is no risk of deterioration in the distribution process.
6)포장6) Packing
건조한 제환을 용기 혹은 팩 등을 이용하여 포장한다.Dry refills are packed in containers or packs.
이와 같은 각 원료의 유효성분으로 구성된 굿나잇은 현재 시판되는 수면제가 단일 성분으로 사용되는데 따른 부작용이 있는 반면, 간단히 섭취가 가능하고 부작용 없이 불면증상을 완화하고 쾌면을 도우는 것으로 나타났다. Good night consisting of the active ingredients of each raw material has the side effects of using the current commercially available sleeping pills as a single ingredient, it is possible to simply ingest and to reduce the symptoms of insomnia without side effects and help sleep.
수면에 반드시 필요한 멜라토닌의 함량을 측정한 결과 전체함량 대비 2.94% 의 멜라토닌을 함유하여 수면 시간의 연장에 도움이 되는 효과를 증명하였다. <실험1>As a result of measuring the amount of melatonin necessary for sleep, it contained 2.94% of the total content of melatonin, which proved to be effective in prolonging the sleep time.
흰쥐를 이용하여 로라제팜(lorazepam;진정제로 사용하는 약물)과 비교실험 하여 운동기능에 미치는 영향을 관찰함으로써 부작용이 없음을 확인하였다. <실험2>The rats were compared with lorazepam (a drug used as a tranquilizer) to observe the effects on motor function and confirmed no side effects.
쥐를 이용한 수면시간연장 실험에서도 굿나잇을 섭취했을 때 확실한 수면시간연장을 확인하였다. <실험3>Sleep time extension experiments using rats also confirmed a clear sleep time extension when ingested Goodnight.
수면에 문제가 있는 사람을 대상으로 굿나잇을 섭취했을 때 나타나는 반응을 테스트함으로써 쾌면에 도움이 됨을 확인하였다.<실험4>Tests on reactions to good night's intake in people with sleep problems were found to be beneficial to sleep.
<실험1> 멜라토닌의 함량 측정
1. 시험방법1. Test Method
(1) 굿나잇에서 멜라토닌 추출 : 에탄올(HPLC grade)을 이용하여 원심분리 (5000rpm, 5min) 및 초음파(15min)추출 후 필터링한다.(참고문헌, HPLC를 이용한 멜라토닌 측정 : 용인대학교 논문집 2001년 19호 - 최돈찬, 임시내)(1) Melatonin Extraction from Good Night: Filtered after centrifugation (5000rpm, 5min) and ultrasound (15min) extraction using ethanol (HPLC grade). (Reference, Melatonin Determination using HPLC: Yongin University, 2001, 19, 2001 -Don Chan Choi, Temporary)
(2) 분석기기 : HPLC(Agilent1200)(2) Analyzer: HPLC (Agilent1200)
컬럼 : C18 Column: C18
이동상 : KH2PO4:MeOH=60:40, 0.8㎖/min Mobile phase:
디텍터 : UV, 200nm Detector: UV, 200nm
(3) 스탠다드(standard) 용액 : 에탄올에 멜라토닌 스탠다드(standard;분말 100%)를 녹여 10%, 20%, 30%의 용액을 제조한다.(3) Standard solution: Dissolve melatonin standard (100% powder) in ethanol to prepare 10%, 20%, 30% solution.
(4) 시료용액 제조(4) Sample Solution Preparation
에탄올 100㎖에 굿나잇 10%용액을 만든 후 진공농축하여 18.7㎖로 만든 용액을 시료용액으로 한다. Make Goodnight 10% solution in 100 ml of ethanol, and concentrate it in vacuo to make 18.7 ml.
2. 시험결과2. Test result
굿나잇에서 멜라토닌 피크(peak)는 15.668%로 측정되었다. Melatonin peak at Goodnight was measured to be 15.668%.
시료용액의 제조에서 18.7/100으로 농축하였으므로 최종적으로 굿나잇에 함유된 멜라토닌 함량은 2.92992%로 측정되었다.(상세한 내용은 도2, 도3에 표시)Since the sample solution was concentrated to 18.7 / 100, the melatonin content in the goodnight was measured as 2.92992%. (Details are shown in Figs. 2 and 3).
<실험2> 운동기능에 미치는 영향<
1. 시험방법.1. Test method.
실험동물로는 체중 20±2g 내외 주령 4내지 5주의 수컷 ICR 생쥐를 효창 Science(대구에 있는 업체)에서 구입하였다. As a test animal, male ICR mice with a body weight of 20 ± 2 g and 4 to 5 weeks of age were purchased from Hyochang Science (company in Daegu).
시료인 '굿나잇'을 분쇄하여 분말로 한 후 분말 540g를 메탄올로 3회 5시간씩 추출하여 추출물 54g(10%)를 얻었다. 이 메탄올 엑스를 시험동물에 투여 용량이 5, 10, 20 ㎎/㎏되게 식품용 유화분산제(상표명;tween80)[tween80:살린(생리식염수;saline)(1:4)]에 용해하여 사용하였다. 대조약물로 로라제팜(lorazepam)을 사용하였다 After crushing the sample 'goodnight' to powder, 540g of powder was extracted three times with methanol for 5 hours to obtain 54g (10%) of the extract. This methanol extract was dissolved in a food emulsifying agent (trade name; tween80) (tween80: saline (saline) (1: 4)) at a dose of 5, 10, or 20 mg / kg. Lorazepam was used as a control drug.
(1) 현수법(1) suspension
수평의 직경 3mm의 금속봉에 앞다리로 5초 이상 매달릴 수 있는 생쥐를 골라 1군 5마리로 실험했다. 굿나잇 메탄올 엑스를 경구로 투여하고 15분, 30분, 60분 및 120분 후에 금속봉에 매달리게 해서 5초 이상 매달릴 수 있는 경우를 작용 없음이라고 판정하였다.Five mice in a group were selected to select mice that could hang for more than 5 seconds with their forelimbs on a horizontal 3mm diameter metal rod. After 15 minutes, 30 minutes, 60 minutes and 120 minutes of oral administration of Goodnight Methanol X, it was determined that no action was allowed to be suspended on a metal rod for more than 5 seconds.
(2) 경사판법(2) inclined plate method
40도 경사진 유리판 위에 5초 이상 정지해 있을 수 있는 생쥐를 골라 1군 5마리로 실험하였다. 굿나잇 메탄올 엑스를 경구로 투여하고 15분, 30분, 60분 및 120분 후에 경사진 유리판에 놓아 5초 이상 정지할 수 있는 경우를 작용 없음이라고 판정하였다.Mice that could be stationary for more than 5 seconds on a 40 degree inclined glass plate were selected and tested in 5 groups. After 15 minutes, 30 minutes, 60 minutes and 120 minutes of oral administration of Goodnight Methanol X, it was determined that no action was allowed to be placed on an inclined glass plate for more than 5 seconds.
(3) Rota-rod법(3) Rota-rod method
생쥐를 사용하여 전봉(직경 3㎝, 매분 6회전) 위에 올려놓고 2분 이상 떨어지지 않는 동물을 골라 1군 5마리로 해서 실험하였다. 굿나잇 메탄올 엑스를 경구로 투여하고 15분, 30분, 60분 및 120분 후에 회전봉위에 올려놓고 낙하할 때까지의 시간을 측정한다. 역시 4분 이상 떨어지지 않았던 경우를 작용 없음이라고 판정하였다.Using mice, the animals were placed on the jeonbong (3 cm in diameter, 6 rotations per minute), and the animals that did not fall for more than 2 minutes were selected as 5 groups of 1 group. After 15 minutes, 30 minutes, 60 minutes and 120 minutes of oral administration of Goodnight Methanol X, the time until the drop is placed on the rotating rod and measured. Again, it was judged that there was no action when it did not fall more than 4 minutes.
2. 실험결과2. Experimental Results
(1) 현수법(1) suspension
Innate reflex(무조건반사작용)의 하나인 visual placing(정확한 위치)과 holding reflex(붙들기 반사)를 관찰한 결과 굿나잇 메탄올 추출물에 의해 이들의 reflex는 거의 억제되지 않음을 보였다. 한편 로라제팜(lorazepam)의 농도(3, 5㎎/㎏)에서는 이들의 reflex(반사작용)가 억제되었으나 시간이 경과한 후 회복됨을 볼 수 있었다. (표 1, 표 2)Observations of visual placing and holding reflex, one of the innate reflexes, showed that the reflex was hardly inhibited by the Goodnight methanol extract. On the other hand, the concentration of lorazzepam (lorazepam) (3, 5 ㎎ / ㎏) was suppressed their reflex (reflection), but was found to recover after time. (Table 1, Table 2)
표 1. vehicle(사료만 투입)과 굿나잇, lorazepam을 투여한 쥐의 정확한 위치선정 결과Table 1. Precise positioning results for rats receiving vehicle (feed only), goodnight and lorazepam
표 2. vehicle(사료만 투입)과 굿나잇, lorazepam을 투여한 쥐의 붙들기 반사 결과Table 2. Results of Catch Reflexes in Mice Treated with Vehicle (Good Feed Only), Goodnight, and Lorazepam
(2) 경사판법(2) sloped plate method
굿나잇 메탄올 추출물을 경구로 투여한 후 경사판에서 시행한 결과에서도 굿나잇 메탄올 엑기스 10, 20㎎/㎏에서 실험 초기에 억제되는 경향을 보였으나 120분에서는 거의 회복되었다. 그러나 로라제팜의 경사판법 시험에서 reflex(반사작용)가 현저히 억제되었고 억제시간도 오래 지속되었다. (표 3)Even after the oral administration of Goodnight methanol extract, it was shown to be suppressed at the beginning of the experiment with
표 3. vehicle(사료만 투입)과 굿나잇, 로라제팜(lorazepam)을 투여한 쥐의 경사판 테스트 결과Table 3. Results of gradient plate tests in rats receiving vehicle (feed only), goodnight and lorazepam
(3) 회전봉법(3) rotating rod method
굿나잇 메탄올 추출물을 경구로 투여하고 rota-rod test(회전봉테스트)를 측정한 결과 대조군과 큰 차이를 보이지 않았다. 한편 lorazepam은 treadmill(트레드밀) 반응이 고용량에서 현저히 감소되었다.(표 4)Good night methanol extracts were orally administered and the rota-rod test (rotary rod test) showed no significant difference from the control group. Lorazepam, on the other hand, significantly reduced the treadmill response at high doses (Table 4).
표 4. vehicle(사료만 투입)과 굿나잇, lorazepam을 투여한 쥐의 회전봉테스트 결과Table 4. Results of a spinning rod test in rats receiving vehicle (feed only), goodnight and lorazepam
< 실험3 > 수면시간에 미치는 영향<
1. 실험방법1. Experimental method
실험동물로는 체중 20±2g 내외 주령 4내지 5주의 수컷 ICR 생쥐를 효창 Science(대구)에서 구입하였다. 시료인 '굿나잇'을 분쇄하여 분말로 한 후 분말 540g를 메탄올로 3회 5시간씩 추출하여 추출물 54g(10%)를 얻었다. 이 메탄올 엑스를 시험동물에 투여 용량이 5, 10, 20 ㎎/㎏되게 식품용 유화분산제(상표명;tween80)[tween80:살린(생리식염수;saline)(1:4)]에 용해하여 사용하였다. 대조약물로 로라제팜(lorazepam)을 사용하였다 As the experimental animals, male ICR mice of 20 to 2 g body weight and 4 to 5 weeks of age were purchased from Hyochang Science (Daegu). After crushing the sample 'goodnight' to powder, 540g of powder was extracted three times with methanol for 5 hours to obtain 54g (10%) of the extract. This methanol extract was dissolved in a food emulsifying agent (trade name; tween80) (tween80: saline (saline) (1: 4)) at a dose of 5, 10, or 20 mg / kg. Lorazepam was used as a control drug.
(1) 단회 투여(1) single dose
생쥐를 1군에 5마리로 하여 실험하였다. 로라제팜(lorazepam)투여 15분, 굿나잇 메탄올 엑스를 경구로 투여하여 30분후에 phentobarbitad sodium(펜토바비탈) 30㎎/㎏을 복강 주사하여 righting reflex(정향반사 : 쥐를 supine position(바로 누운 자세)으로 하면 상체를 일으키면서 돌림)의 소실에서 회복까지의 시간을 측정하였다.Mice were experimented with 5 mice per group. After 15 minutes of lorazepam, oral administration of Goodnight Methanol X, 30 minutes after injection of phentobarbitad sodium (30 mg / kg), the righting reflex (reflection reflection: rats in supine position) In this case, the time from disappearance to recovery was measured while raising the upper body.
(2) 반복투여(2) repeated administration
생쥐를 1군에 5마리로 하여 실험하였다. 굿나잇 메탄올 엑스(5, 10, 20㎎/㎏) 및 lorazepam(0.025, 0.05, 0.1㎎/㎏)을 1주일간 경구투여 하고서 시험당일 30분 후에 phentobarbital sodium(펜토바비탈) 30㎎/㎏을 복강 주사하여 righting reflex(정향 반사 : 쥐를 supine position으로 하면 상체를 일으키면서 몸을 돌림)의 소실에서 회복까지의 시간을 측정하였다.Mice were experimented with 5 mice per group. Good night methanol extract (5, 10, 20 mg / kg) and lorazepam (0.025, 0.05, 0.1 mg / kg) were administered orally for 1 week, 30 minutes after the test, 30 mg / kg of phentobarbital sodium (pentobabital) was intraperitoneally injected. We measured the time from loss of righting reflex (turning the body while raising the upper body when the rat was in the supine position) to recovery.
2. 실험결과 2. Experimental Results
(1) 단회투여(1) Single dose
Phentobarbital sodium에 의하여 수면시간은 굿나잇 메탄올 추출물을 경구로 투여한 대조군보다 다소 증가하는 경향을 보였다.(표 5)Sleeping time by phentobarbital sodium tended to increase slightly compared to the control group administered orally goodnight methanol extract (Table 5).
표 5. vehicle(대조군)과 굿나잇, lorazepam을 투여한 쥐의 수면시간 결과Table 5. Sleep time results in rats treated with vehicle (control), goodnight and lorazepam
생쥐를 굿나잇과 로라제팜 에탄올 추출물을 1회 경구 투여하고 30분후 펜토바비탈(30mg/kg)에 용해하여 복강 주사하였다. 값은 5번 실험하여 평균±표준편차로 나타내었다. Duncan's new multiple(둔칸의검증법) 검사로 유의차를 나타내었다.(p<0.05)Mice were intraperitoneally injected with penitebarbital (30 mg / kg) after 30 minutes of oral administration of Goodnight and Lorazepam ethanol extracts. Values were expressed as mean ± standard deviation after five experiments. Duncan's new multiple test showed significant differences (p <0.05).
(2)반복투여 효과(2) repeated dose effect
Phentobarbital sodium을 투여하기 전 굿나잇 메탄올 엑기스 및 lorazepam을 1주일간 경구 투여하고서 단회투여효과와 비교하였을 때 수면시간은 굿나잇 메탄올 추출물 및 lorazepam을 경구로 단회투여 한때 보다는 다소 증가하는 경향을 보였다.(표 6)Sleeping time tended to increase somewhat compared to the single-dose administration of goodnight methanol extract and lorazepam for 1 week before oral administration of phentobarbital sodium (Table 6).
표 6. vehicle(대조군)과 굿나잇, lorazepam을 투여한 쥐의 수면시간 결과Table 6. Sleep time results in rats treated with vehicle (control), goodnight, and lorazepam
생쥐에게 굿나잇과 로라제팜의 에탄올 추출물을 하루에 1회 경구 투여하고 1주일간 반복 투여하고 샘플 최종 투여 30분후 펜토바비탈(30mg/kg)에 용해하여 복강 주사하였다. 값은 5번 실험하여 평균±표준편차로 나타내었다. 데이터는 Duncan's new multiple 검사로 유의차를 나타내었다.(p<0.05)Mice were injected orally once a day with ethanol extracts of goodnight and lorazepam, and repeatedly administered for 1 week, and dissolved in pentobarbital (30 mg / kg) 30 minutes after the final sample was intraperitoneally injected. Values were expressed as mean ± standard deviation after five experiments. The data showed significant differences with Duncan's new multiple test (p <0.05).
<실험4> 굿나잇 섭취에 따른 수면의 질 개선<Experiment 4> Improvement of sleep quality according to good night intake
1. 시험방법 1. Test Method
(1)시험 샘플 : 굿나잇(산조인 28.5%, 연자육 24%, 연근 24%, 토란대 22%, 염화마그네슘 1.5%)(1) Test sample: Goodnight (sanjoin 28.5%, lotus root 24%, lotus root 24%, taro 22%, magnesium chloride 1.5%)
(2)피험자수 : 91명(20대-1명, 30대-1명, 40대-17명, 50대-32명, 60대-30명, 70대-10명)(2) Number of subjects: 91 (20s-1 people, 30s-1 people, 40s-17 people, 50s-32 people, 60s-30 people, 70s-10 people)
(3)시험기간 : 섭취기간은 한 달(30일)이상 연속으로 하루 2번 이상 섭취.(3) Test period: Intake period is taken at least twice a day for more than one month (30 days).
(4)섭취방법 : 한 스푼(4.5g)을 물과 함께 삽취(4) Intake Method:
(5) 시험대상 (5) Test subject
*선택기준 * Selection criteria
- ① 연령 20세 이상 남녀-①
- ② 수면에 불편을 느끼는 자-② Those who have trouble sleeping
*제외기준 * Exclusion Criteria
- ① 배경 조사의 결과, 수면에 문제가 없다고 판단된 자-① As a result of the background check, the person judged that there is no problem with sleep
- ② 임신, 임신하였다고 생각되는 부인, 수유중의 부인-② Pregnant, pregnant woman who is pregnant, lactating wife
- ③ 중증 화분증, 위장질환, 간질환, 심장질환, 심질환을 가진 자-③ People with severe hay fever, gastrointestinal disease, liver disease, heart disease and heart disease
- ④ 수면에 영향을 미치는 약(감기약, 항알레르기약 등을 포함한다), 보조제(supplement)를 시험기간에 중단할 수 없는 자④ Those who cannot stop the medicine (including cold medicine, anti-allergic medicine, etc.) and supplements that affect sleep during the trial period
*조사항목* Investigation item
- ① 배경조사 : 연령, 성별, 생활습관, 수면상태를 관찰기간에 기재한다.① Background Check: Write your age, gender, lifestyle, and sleep status during the observation period.
- ② 수면조사 : 수면의 질, 잠에서 깼을 때의 상쾌감 등을 섭취전과 섭취후에 기재시킨다.-② Sleep investigation: Write the quality of sleep and refreshment when waking up before and after intake.
2. 시험 결과 2. Test result
(1)수면장애 개선 굿나잇 섭취에 따른 수면의 질 개선 1.(1) Improve sleep disorders Improve sleep quality according to
상기의 결과에서 알 수 있는 바와 같이 굿나잇을 섭취 후 취침 전 잠들기가 상당히 개선됨을 확인할 수 있었다.As can be seen from the above results, it was confirmed that after ingestion of goodnight, sleep before bedtime was significantly improved.
(2) 수면장애 개선 굿나잇 섭취에 따른 수면의 질 개선 2.(2) Improve sleep disorders Improve sleep quality according to
상기의 결과에서 알 수 있는 바와 같이 굿나잇을 섭취 후 수면 후 아침에 눈 뜨기가 쉬워져 수면 후 개운함을 느꼈음을 확인할 수 있었다.As can be seen from the above results, it was easy to open the eyes in the morning after sleep after ingesting goodnight, and it was confirmed that the freshness was felt after sleep.
(3) 수면장애 개선 굿나잇 섭취에 따른 수면의 질 개선 3.(3) Improve sleep disorders Improve sleep quality according to
상기의 결과에서 알 수 있는 바와 같이 굿나잇을 섭취 후 숙면감이 58%이상으로 섭취전의 2%에 비해 상당히 개선됨을 확인할 수 있었다.As can be seen from the above results, good night's sleep after ingesting good night was 58% or more, compared to 2% before intake.
(4) 수면장애 개선 굿나잇 섭취에 따른 수면의 질 개선 4.(4) Improve sleep disorders Improve sleep quality according to good night intake 4.
상기의 결과에서 알 수 있는 바와 같이 굿나잇을 섭취 후 꿈을 꾸지 않고 숙면을 취할 수 있었다.As can be seen from the above results, after ingesting goodnight, it was possible to take a good night's sleep without dreaming.
상기의 실험을 통해서 굿나잇을 복용한 후 굿나잇에 함유된 멜라토닌 각 성분들의 효과에 의해 숙면을 취함은 물론 쾌면에도 효과가 있음을 확인할 수 있었다.Through the above experiment, after taking good night, it was confirmed that the effect of each component of the melatonin contained in the good night, as well as taking a good night's sleep.
도 1은 본 발명에서 제시하는 바람직한 제조방법의 공정을 보인 블록도 1 is a block diagram showing a process of the preferred manufacturing method proposed in the present invention
도 2는 HPLC를 이용한 멜라토닌 분석을 행한 그래프 - Calibration Figure 2 is a graph of melatonin analysis using HPLC-Calibration
도 3은 HPLC를 이용한 멜라토닌 분석을 행한 그래프 - melatonin 분석치3 is a graph of melatonin analysis using HPLC-melatonin analysis value
Claims (2)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020090086019A KR100947353B1 (en) | 2009-09-11 | 2009-09-11 | Healthy food composition for improving sleep disturbance and a good-sleep |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020090086019A KR100947353B1 (en) | 2009-09-11 | 2009-09-11 | Healthy food composition for improving sleep disturbance and a good-sleep |
Publications (1)
Publication Number | Publication Date |
---|---|
KR100947353B1 true KR100947353B1 (en) | 2010-03-15 |
Family
ID=42183282
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020090086019A KR100947353B1 (en) | 2009-09-11 | 2009-09-11 | Healthy food composition for improving sleep disturbance and a good-sleep |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR100947353B1 (en) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101289042B1 (en) | 2011-04-11 | 2013-07-23 | 신행연 | health-supporting food using Nelumbinis Semen and manufacturing method thereof |
CN108477607A (en) * | 2018-04-10 | 2018-09-04 | 李钟� | A kind of nutraceutical improving children and infantal sleeping |
KR20180136358A (en) | 2017-06-14 | 2018-12-24 | 국민대학교산학협력단 | Composition for preventing, improving or treating sleep disorders comprising fermentation broth of bacillus subtilis as an effective ingredient |
KR20200043250A (en) | 2018-10-17 | 2020-04-27 | 국민대학교산학협력단 | Composition for preventing, improving or treating sleep disorders comprising fermentation broth of bacillus subtilis and vitamin b6 as an effective ingredient |
CN112205507A (en) * | 2020-09-30 | 2021-01-12 | 米宝有约(北京)医疗科技有限公司 | Composition capable of improving sleep, health food and pharmaceutical preparation as well as preparation method and application of composition |
KR102388769B1 (en) * | 2021-11-02 | 2022-04-21 | 네이처퓨어코리아 주식회사 | Composition for prevention or improvement of sleep disorders comprising Zizyphus Seed powder and Rosae Multiflorae Fructus powder |
WO2023018256A1 (en) * | 2021-08-12 | 2023-02-16 | 주식회사 머스카 | Beverage for inducing sleep and improving sleep quality |
WO2023018255A1 (en) * | 2021-08-12 | 2023-02-16 | 주식회사 머스카 | Use of natural substance for inducing sleep and improving sleep quality |
KR20240040233A (en) | 2022-09-21 | 2024-03-28 | 단태욱 | Coffee manufacturing method and coffee composition with improved sleep quality |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20020089430A (en) * | 2000-04-05 | 2002-11-29 | 타이요 카가꾸 가부시키가이샤 | Compositions for promoting sleep |
KR20070070307A (en) * | 2005-08-24 | 2007-07-04 | 에스에스 세야쿠 가부시키 가이샤 | Sleep-improving pharmaceutical composition |
KR100874020B1 (en) * | 2008-04-23 | 2008-12-17 | 시흥시 | Lotus green tea and its manufacturing method |
-
2009
- 2009-09-11 KR KR1020090086019A patent/KR100947353B1/en active IP Right Grant
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20020089430A (en) * | 2000-04-05 | 2002-11-29 | 타이요 카가꾸 가부시키가이샤 | Compositions for promoting sleep |
KR20070070307A (en) * | 2005-08-24 | 2007-07-04 | 에스에스 세야쿠 가부시키 가이샤 | Sleep-improving pharmaceutical composition |
KR100874020B1 (en) * | 2008-04-23 | 2008-12-17 | 시흥시 | Lotus green tea and its manufacturing method |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101289042B1 (en) | 2011-04-11 | 2013-07-23 | 신행연 | health-supporting food using Nelumbinis Semen and manufacturing method thereof |
KR20180136358A (en) | 2017-06-14 | 2018-12-24 | 국민대학교산학협력단 | Composition for preventing, improving or treating sleep disorders comprising fermentation broth of bacillus subtilis as an effective ingredient |
KR102019296B1 (en) | 2017-06-14 | 2019-09-09 | 국민대학교 산학협력단 | Composition for preventing, improving or treating sleep disorders comprising fermentation broth of bacillus subtilis as an effective ingredient |
CN108477607A (en) * | 2018-04-10 | 2018-09-04 | 李钟� | A kind of nutraceutical improving children and infantal sleeping |
KR20200043250A (en) | 2018-10-17 | 2020-04-27 | 국민대학교산학협력단 | Composition for preventing, improving or treating sleep disorders comprising fermentation broth of bacillus subtilis and vitamin b6 as an effective ingredient |
CN112205507A (en) * | 2020-09-30 | 2021-01-12 | 米宝有约(北京)医疗科技有限公司 | Composition capable of improving sleep, health food and pharmaceutical preparation as well as preparation method and application of composition |
WO2023018256A1 (en) * | 2021-08-12 | 2023-02-16 | 주식회사 머스카 | Beverage for inducing sleep and improving sleep quality |
WO2023018255A1 (en) * | 2021-08-12 | 2023-02-16 | 주식회사 머스카 | Use of natural substance for inducing sleep and improving sleep quality |
KR102388769B1 (en) * | 2021-11-02 | 2022-04-21 | 네이처퓨어코리아 주식회사 | Composition for prevention or improvement of sleep disorders comprising Zizyphus Seed powder and Rosae Multiflorae Fructus powder |
WO2023080409A1 (en) * | 2021-11-02 | 2023-05-11 | 네이처퓨어코리아 주식회사 | Composition for preventing or alleviating sleep disorder, comprising zizyphus seed powder and rosae multiflorae fructus powder |
KR20240040233A (en) | 2022-09-21 | 2024-03-28 | 단태욱 | Coffee manufacturing method and coffee composition with improved sleep quality |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100947353B1 (en) | Healthy food composition for improving sleep disturbance and a good-sleep | |
CN104366510B (en) | Folium Camelliae sinensis theanine health-care food composition and preparation method thereof | |
JP2013501778A (en) | HEALTH SUPPLEMENTAL, FEED, PHARMACEUTICAL COMPOSITION AND METHOD FOR PRODUCING THE SAME CONTAINING CHIASEED AND MACA | |
CN103007146B (en) | Healthcare nutrition powder for enhancing memory ability | |
CN110402138A (en) | The composition for reducing appetite and thirsting for, increasing satiety, improve mood and ease off the pressure | |
CN102499299A (en) | Solid instant Puerh tea for reducing fat and losing weight and preparation process thereof | |
ES2747932T3 (en) | Use of phytoecdisonas in the preparation of a composition to act on the metabolic syndrome | |
KR100463130B1 (en) | The food to improve the sexual function of man | |
AU2005291420B2 (en) | Use of lavender oil for the prophylaxis and treatment of neuro asthenia, somatization disorders and other diseases associated with stress | |
CN106492104A (en) | A kind of breast enlargement compositionss and preparation method thereof | |
CN103041137A (en) | Pharmaceutical composition for preventing and treating senile dementia, and preparation method thereof | |
CN102697781A (en) | Application of trigonelline in preparation of medicament for preventing and treating diabetes and complication thereof | |
US20230125425A1 (en) | Traditional chinese medicine extract composition with function of regulating depressive emotion and preparation method and traditional chinese medicine preparation thereof | |
WO2014154008A1 (en) | Purgative composition, preparation method therefor and application thereof | |
CN109999088A (en) | A kind of compound preparation and its application with effect of relaxing bowel | |
CN110448668A (en) | A kind of Chinese medicine composition keeping gentle constitution, broken wall composition and preparation method thereof | |
CN103417799B (en) | A kind of application of Chinese medicine composition in the medicine for preparing treatment anaemia | |
CN114177303A (en) | Bowel relaxing composition and preparation method thereof | |
CN102711779A (en) | Composition containing black ginseng extracts for preventing or treating liver cancer | |
CN102908396A (en) | Chinese medicinal composition for promoting sleeping and preparation method thereof | |
CN103272146B (en) | Medicine composition used for preventing and treating alcoholic fatty liver and preparation method thereof | |
CN103404701B (en) | A kind ofly improve veterinary composition of poultry mouthfeel and its production and use | |
JP2007191478A5 (en) | ||
CN110384782A (en) | It is a kind of to intervene the Chinese medicine composition of phlegm-dampness constitution, broken wall composition and preparation method thereof | |
CN110720527A (en) | Traditional Chinese medicine weight-losing tea |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
A302 | Request for accelerated examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20130131 Year of fee payment: 4 |
|
FPAY | Annual fee payment |
Payment date: 20140120 Year of fee payment: 5 |
|
FPAY | Annual fee payment |
Payment date: 20150226 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20160229 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20200213 Year of fee payment: 11 |